Brain PET scans change management of patients with possible Alzheimer’s
Michael J. Pontecorvo, PhD, of Eli Lilly’s Avid Radiopharmaceuticals and colleagues at numerous medical institutions sent 618 patients for florbetapir (18F) PET neuroimaging, then randomized them 1:1 for amyloid assessment either immediately (information group) or after one year (control group). {read more here}
Paraneoplastic syndrome is a rare and poorly understood systemic manifestation of malignancy that can involve multiple organ systems. Detection of the underlying malignancy is key to treatment. Sara Sheikhbahaei and colleagues from the Johns Hopkins University School of Medicine in Baltimore, Maryland, performed a systematic review and meta-analysis using published studies assessing the potential utility of whole-body18F-fluorodeoyglucose (FDG) with positron emission tomography (PET) or hybrid PET/computed tomography (PET/CT). {read more here}
An artificial intelligence (AI) algorithm can recognize the signatures of dementia on amyloid PET scans two years before the onset of symptoms, according to research published online recently in Neurobiology of Aging. {read more here}
A multidisciplinary team of experts from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine and Molecular Imaging collaborated and have released a joint consensus document on the role of F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. {read more here}